Roep Reducing Proinsulin-Specific CD 8 + T Cells in Type 1 Diabetes Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically

diabetes. larger studies, a plasmid encoding proinsulin could serve as a targeted means of immunosuppression for type 1 T cells. If these data hold true in + T cells. No difference was observed in cytokine production by CD4 + unrelated CD8 T cells, but not + immune responses in these patients and found that there was a decrease in proinsulin-specific CD8 cell function. The authors then examined the β a readout of −− the experimental group had improved C-peptide levels proinsulin-expressing engineered plasmid or PBS vehicle. They observed no serious adverse events. The subjects in The authors randomized patients recently diagnosed with type 1 diabetes to receive various doses of either a patients. cell function in type 1 diabetes β demonstrate that an engineered plasmid that expresses proinsulin can preserve et al. target the specific autoreactive cells without suppressing the rest of the immune response. Now, Roep of the pancreas. One way to block this response is through immunosuppression; however, it has proven difficult to Type 1 diabetes is an autoimmune disease where an inflammatory response destroys the insulin-producing cells Diabetes Trial Hits Its Mark

[1]  O. Kordonouri,et al.  GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus , 2013 .

[2]  J. Drijfhout,et al.  Islet-Specific CTL Cloned from a Type 1 Diabetes Patient Cause Beta-Cell Destruction after Engraftment into HLA-A2 Transgenic NOD/SCID/IL2RG Null Mice , 2012, PloS one.

[3]  C. Stokes,et al.  Preexisting Autoantibodies Predict Efficacy of Oral Insulin to Cure Autoimmune Diabetes in Combination With Anti-CD3 , 2012, Diabetes.

[4]  M. Atkinson,et al.  Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients , 2012, The Journal of experimental medicine.

[5]  M. V. von Herrath,et al.  Humanizing Animal Models: A Key to Autoimmune Diabetes Treatment , 2011, Science Translational Medicine.

[6]  Bart O. Roep,et al.  Simultaneous Detection of Circulating Autoreactive CD8+ T-Cells Specific for Different Islet Cell–Associated Epitopes Using Combinatorial MHC Multimers , 2010, Diabetes.

[7]  J. Ringers,et al.  Accumulation of autoreactive effector T cells and allo-specific regulatory T cells in the pancreas allograft of a type 1 diabetic recipient , 2009, Diabetologia.

[8]  H. Garren,et al.  Improved Efficacy of a Tolerizing DNA Vaccine for Reversal of Hyperglycemia through Enhancement of Gene Expression and Localization to Intracellular Sites , 2008, The Journal of Immunology.

[9]  H. Kolb,et al.  Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes , 2008, Diabetes Care.

[10]  J. Drijfhout,et al.  Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes , 2005 .

[11]  D. Hafler,et al.  Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope , 2005, Nature.

[12]  J. Krischer,et al.  Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. , 2005, Diabetes care.

[13]  Mark Peakman,et al.  Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. , 2004, The Journal of clinical investigation.

[14]  P. Fontoura,et al.  An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems 1 , 2003, The Journal of Immunology.

[15]  P. Bingley,et al.  The prevalence of insulin autoantibodies at the onset of Type 1 diabetes is higher in males than females during adolescence , 2003, Diabetologia.

[16]  M. Knip,et al.  Intranasally administered insulin intended for prevention of type 1 diabetes—a safety study in healthy adults , 2003, Diabetes/metabolism research and reviews.

[17]  L. Harrison,et al.  Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. , 2003, Diabetes.

[18]  M. Rewers,et al.  Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. V. von Herrath,et al.  DNA immunization to prevent autoimmune diabetes. , 1999, The Journal of clinical investigation.

[20]  P. Bingley,et al.  Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. , 1998, Diabetes.

[21]  H. Chase,et al.  Altered immune response to insulin in newly diagnosed compared to insulin-treated diabetic patients and healthy control subjects , 1997, Diabetologia.

[22]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[23]  J. Drijfhout,et al.  Autoreactive CD 8 T cells associated with cell destruction in type 1 diabetes , 2005 .

[24]  G. A. Fleming,et al.  C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. , 2004, Diabetes.

[25]  Bart O. Roep Dr. The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure , 2003, Diabetologia.